Table 4 Cox proportional hazard analysis for sex difference in relationship to metastasis-free survival in various clinical subgroups (Male = 1)

Overall

516

1.328

0.805 – 2.193

0.267

Age, years

<58

262

0.957

0.496 – 1.847

0.896

≥58

254

1.731

0.793 – 3.779

0.169

Anti-HCV

Negative

381

1.272

0.701 – 2.307

0.429

Positive

135

1.369

0.523 – 3.583

0.522

HBsAg

Negative

157

2.159

0.876 – 5.321

0.094

Positive

359

1.049

0.574 – 1.918

0.877

Liver cirrhosis

No

219

1.272

0.615 – 2.632

0.517

Yes

297

1.373

0.688 – 2.742

0.368

Microvascular invasion

No

343

1.024

0.541 – 1.937

0.943

Yes

173

1.324

0.562 – 3.119

0.521

Macrovascular invasion

No

449

1.331

0.758 – 2.340

0.320

Yes

67

1.147

0.379 – 3.477

0.808

Histology grade

<3

233

2.094

0.816 – 5.370

0.124

≥3

283

1.076

0.592 – 1.958

0.809

Capsule

No

141

0.868

0.366 – 2.056

0.747

Yes

375

1.550

0.831 – 2.890

0.168

Tumor number

1

306

1.242

0.639 – 2.415

0.523

>1

210

1.362

0.631 – 2.940

0.431

Ascites

No

477

1.246

0.753 – 2.061

0.392

Yes

39

31.863

0.002 - 458965

0.479

Alcoholism

No

383

1.248

0.736 – 2.116

0.411

Yes

133

20.884

0.000 - 1274875

0.589

Largest tumor size, cm

≤4

242

1.851

0.769 – 4.456

0.169

>4

274

1.060

0.575 – 1.952

0.852

AFP, ng/mL

≤35

270

3.572

1.104 – 11.553

0.034

>35

246

0.956

0.534 – 1.714

0.881

Albumin, g/L

≤4

279

1.378

0.728 – 2.606

0.325

>4

237

1.356

0.601 – 3.061

0.463

Bilirubin, mg/dL

≤0.8

263

1.418

0.746 – 2.694

0.287

>0.8

253

1.154

0.511 – 2.604

0.730

PT, sec

<12

259

1.105

0.559 – 2.184

0.774

≥12

257

1.572

0.740 – 3.340

0.239

PT, INR

<1.1

270

1.189

0.607 – 2.328

0.614

≥1.1

246

1.496

0.700 – 3.195

0.299

Creatinine, mg/dL

≤1

294

1.325

0.776 – 2.265

0.303

>1

222

22.955

0.098 - 5387

0.261

AST, U/L

≤39

262

1.124

0.538 – 2.351

0.756

>39

254

1.511

0.761 – 3.000

0.238

ALT, U/L

≤40

255

1.695

0.849 – 3.384

0.134

>40

261

1.040

0.503 – 2.153

0.915